JSP191 for Chronic Granulomatous Disease
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the idea that JSP191 for Chronic Granulomatous Disease (also known as: JSP191, AMG 191) is an effective treatment?
The available research does not provide specific data on JSP191 for treating Chronic Granulomatous Disease. Instead, it discusses other treatments like hematopoietic stem cell transplantation (HSCT), which has shown improved survival rates of over 84-90%. It also mentions gene therapy as a promising future approach. Without specific data on JSP191, we cannot compare its effectiveness to these treatments.12345
What safety data exists for JSP191 treatment in Chronic Granulomatous Disease?
The provided research does not contain specific safety data for JSP191 or AMG 191 in the treatment of Chronic Granulomatous Disease. The articles focus on the quality of life, immunological aspects, and treatment options like hematopoietic stem cell transplantation and gene therapy for CGD, but do not mention JSP191 or AMG 191.36789
Is the drug JSP191 a promising treatment for Chronic Granulomatous Disease?
What is the purpose of this trial?
Background:Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD.Objective:To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated donor.Eligibility:People aged 4 to 65 years with CGD who require a transplant.Design:Participants will be screened. Part of the screening will help to identify the best match to a transplant donor. Participants will have a physical exam, including dental and eye exams. They will have blood and urine tests. They will have tests of their breathing and heart function. A bone marrow sample will be taken. They will have their stem cells collected.Participants will have a catheter inserted into a vein in their chest. It will remain in place for the entire period of transplant and recovery.Participants will be in the hospital 40 to 50 days for the transplant. This will include a conditioning phase, to prepare their body for the procedure, as well as the transplant and recovery phases. As part of the conditioning phase, participants will receive JSP191 through a vein for 1 hour.After discharge, participants will have follow-up visits 2 times a week for 100 days. Additional follow-up visits will continue for 5 years....
Research Team
Elizabeth M Kang, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria
This trial is for people aged 4-65 with Chronic Granulomatous Disease (CGD) needing a stem cell transplant and have an unrelated matched donor. Participants must be able to stay near the NIH for 3 months post-transplant, use contraception, and not have major illnesses or organ failure that could affect survival after the transplant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning
Participants undergo conditioning with JSP191, alemtuzumab, and total body irradiation to prepare for the transplant
Transplant and Recovery
Participants receive a high-dose donor graft infusion followed by post-transplant cyclophosphamide
Follow-up
Participants are monitored for safety and effectiveness after treatment, including engraftment and GvHD assessment
Treatment Details
Interventions
- JSP191
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor